Zentalis Says FDA Has Lifted Partial Clinical Hold On Studies Of Azenosertib, Its Novel, Selective, And Orally Bioavailable Inhibitor Of WEE1
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals announced that the FDA has lifted the partial clinical hold on its azenosertib studies, allowing the company to resume enrollment in all ongoing clinical trials without changes to the development plan.
September 16, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in all ongoing trials. This is a positive development for Zentalis as it can continue its clinical development program without changes.
The lifting of the FDA hold is a significant regulatory milestone for Zentalis, allowing them to proceed with their clinical trials as planned. This development is likely to be viewed positively by investors, potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100